MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Journal of Cancer Research and Clinical Oncology 2018 August 3 [Link] Liu XL, Zuo R, Ou WB Abstract PURPOSE: Lung cancer and mesothelioma are two types of respiratory disease that have fatal courses and poor prognoses. Although a substantial number of targeted small molecules and antibody drugs have been developed, the 5-year survival rates of […]

Comments Off on The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Human Pathology 2018 July 18 [Link] Hui S, Guo-Qi Z, Xiao-Zhong G, Chun-Rong L, Yu-Fei L, Dong-Liang Y Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer with poor prognosis and several biomarkers have been suggested for screening of MPeM. The aim of our study was to evaluate the prognostic significanceas of IMP3 and Fli-1 […]

Comments Off on IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Frontiers in Genetics 2018 July 4 [Link] Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y Abstract Malignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is […]

Comments Off on Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.

International Journal of Medical Sciences 2018 June 4 [Link] Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, Ochoa-Vázquez MD, Torre-Bouscoulet L, Acosta-Saavedra LC, Sada-Ovalle I, García-Figueroa J, Alvarado-Cabrero I, Castillo-González P, Báez-Saldaña AR, Pérez-Padilla JR, Osnaya-Juárez J, Rivera-Rosales RM, García-Bazán EM, Bautista-Aragón YL, Lazcano-Hernandez E, Munguía-Canales DA, Argote-Greene LM, Taeger D, […]

Comments Off on Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.

Absence of calretinin protein expression in malignant mesotheliomas from asbestos-exposed NF2+/- mice and mouse mesothelioma cell lines from various mouse strains.

Biomarker Research 2018 June 6 [Link] Blum W, Henzi T, Châtel-Soulet HE, Pecze L, Rodriguez JW, Vrugt B, Schwaller B Abstract BACKGROUND: Calretinin is the most widespread positive marker for the immunohistochemical identification of malignant mesothelioma (MM) and was proposed to serve as a blood-based biomarker. Functionally, evidence has accumulated that calretinin might be implicated […]

Comments Off on Absence of calretinin protein expression in malignant mesotheliomas from asbestos-exposed NF2+/- mice and mouse mesothelioma cell lines from various mouse strains.

Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Oncotarget 2018 April 27 [Link] Augeri S, Capano S, Morone S, Fissolo G, Giacomino A, Peola S, Drace Z, Rapa I, Novello S, Volante M, Righi L, Ferrero E, Ortolan E, Funaro A Abstract BACKGROUND: CD157/Bst1 glycoprotein is expressed in >85% of malignant pleural mesotheliomas and is a marker of enhanced tumor aggressiveness. RESULTS: In […]

Comments Off on Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells

Oncotarget 2018 April [Link] Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F Abstract PURPOSE: Kisspeptin signaling, via its receptors GPR54, could be an essential players in the inhibition of mesothelioma progression, invasion […]

Comments Off on Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells

Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)

BMJ Open Respiratory Research 2018 February 19 [Link] de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, Maskell NA Abstract INTRODUCTION: Pleural malignancy, particularly malignant pleural mesothelioma (MPM) is increasing in incidence due to the long latency period from exposure to asbestos to development of the disease. MPM can be challenging […]

Comments Off on Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)

Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

Lung Cancer 2018 April [Epub 2018 February 3] [Link] Tsim S, Humphreys CA, Cowell GW, Stobo DB, Noble C, Woodward R, Kelly CA, Alexander L, Foster JE, Dick C2, Blyth K Abstract INTRODUCTION: Pleural Malignancy (PM) is often occult on subjective radiological assessment. We sought to define a novel, semi-objective Magnetic Resonance Imaging (MRI) biomarker […]

Comments Off on Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

Podoplanin – an emerging cancer biomarker and therapeutic target

Cancer Science 2018 March 25 [Epub ahead of print] [Link] Krishnan H et. al. Abstract Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts (CAFs), and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition (EMT), migration, invasion, metastasis, […]

Comments Off on Podoplanin – an emerging cancer biomarker and therapeutic target